Related to AstraZeneca, Targacept’s TC-5214 Fails as Adjunct to Antidepressants

• Promising Data for Type 1 and 2 Diabetes Candidates Presented at ADA Meeting
  
• AstraZeneca and PTC Ally On Small Molecule Drugs against Cancer
  
• Forest and Pierre Fabre Report Positive Data from Second Phase III Antidepressant Trial
  
• Phase IIIb Study Shows Benefits of Combining Onglyza with Insulin for Type 2 Diabetes
  
• AstraZeneca Pays Dynavax $3M to Speed Up Start of Asthma Drug Trials
  
• Neoprobe Licenses AstraZeneca’s Alzheimer Plaque Imaging Agent
  
• Hutchinson, AstraZeneca Ink Deal for c-Met Inhibitor with $20M Up Front
  
• Pierre Fabre, Forest Report Positive Phase III Data from Depression Study
  
• AstraZeneca Forges Pact Around Five Amgen Clinical-Stage Anti-Inflammatory mAbs
  
• NMR Structural Biology Firm Signs First Drug Discovery Collaboration with AstraZeneca
  
• Pierre Fabre, Forest Report Positive Data from Third Phase III Depression Trial
  
• AstraZeneca, Rigel Sign Potentially $100M Asthma Drug Deal
  
• Horizon, AstraZeneca Seek Kinase-Targeting Cancer Drugs
  
• AstraZeneca, BIND Enter $200M+ Cancer Nanomedicine Agreement
  
• AstraZeneca Licenses Antidepressant Compounds Discovered in Mayo Clinic and Virginia Tech Collaboration
  
• Targacept to Receive $10M as AstraZeneca Scales Up CNS Disorder Partnership
  
• Targacept and AZ Restructure Partnership as Success Proves Elusive
  
• AstraZeneca Provides $200M Up Front to Develop Targacept’s Late-Stage Candidate for Depression
  
• First Phase III Study with Targacept and AstraZeneca’s Adjunctive Antidepressant Misses Primary Endpoint
  
• Targacept, AstraZeneca Ditch Depression Drug After All Four Phase III Studies Fail